Use of toll-like receptor agonist for treating cancer
AssigneeCleveland BioLabs, Inc.
InventorsAnatoli Gleiberman, Lyudmila Burdelya, Andrei Gudkov
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.
Claims19
A method of treating a cancer present in a tissue that expresses a Toll-Like Receptor 5 (TLR5), comprising administering an effective amount of a TLR5 agonist to a subject in need thereof,
- wherein the cancer does not express TLR5,
- wherein the TLR5 agonist is flagellin or a flagellin derivative, and
- wherein the TLR5-expressing tissue is colon.
A method of reducing recurrence of a cancer that does not express Toll-Like Receptor 5 (TLR5) in a subject in need thereof, comprising administering to the subject an effective amount of a TLR5 agonist, wherein the cancer is present in colon tissue that expresses TLR5, and wherein the TLR5 agonist is flagellin or a flagellin derivative.
A method of treating a metastatic cancer that does not express Toll-Like Receptor 5 (TLR5) but is present in colon tissue that expresses TLR5, comprising administering an effective amount of a flagellin or a flagellin derivative to a subject in need thereof.
Dependencies are inferred from the claim text.